MedPath
Found 2 clinical trials|View Analysis
Sort by:

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Phase 2
Active, not recruiting
Conditions
WHO Grade II Glioma
Interventions
Drug: DS-1001b
First Posted Date
2020-07-07
Last Posted Date
2024-12-16
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
25
Registration Number
NCT04458272
Locations
🇯🇵

Hiroshima University Hospital, Hiroshima, Japan

🇯🇵

Kyorin University Hospital, Tokyo, Japan

🇯🇵

Nagoya University Hospital, Nagoya, Aichi, Japan

and more 8 locations

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Not Applicable
Active, not recruiting
Conditions
Glioma
Interventions
Drug: DS-1001b
First Posted Date
2017-01-24
Last Posted Date
2024-03-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
47
Registration Number
NCT03030066
Locations
🇯🇵

National Cancer Center Hospital, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath